Questionnaire on Self-reported Experience of Koebner and Deep-Koebner Phenomenon in Patients With Psoriasis and Psoriatic Arthritis.

Status: Completed
Location: See location...
Study Type: Observational
SUMMARY

PSODEEP 1 is a descriptive digital interview study where we intend to include at least 900 individuals. Individuals with known psoriasis or known psoriatic arthritis will access the digital interview via a QR code distributed via their rheumatology or dermatology department using their smartphones. Data on answers results are stored digitally and can be accessed parallel to recruitment. Questions focus on following fields (all self reported): background information (age/sex), disease duration, disease course/fluctuation, disease diagnosis as given by MD, disease treatment, disease severity, disease classification, disease triggers, screening of psoriatic arthritis (questions derived from PEST questionnaire), Koebner occurence, variability in Koebner over time, deep-Koebner occurence and variability in Deep-Koebner over time.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• MD diagnosis of psoriasis and/or psoriasis arthritis

• Age over 18 years

• Ability to read and understand written questions

• Having/ability to use smartphone

• Given consent

Locations
Other Locations
Sweden
Hudkliniken Skånes Universitetssjukhus
Malmo
Time Frame
Start Date: 2022-10-19
Completion Date: 2024-02-14
Participants
Target number of participants: 3064
Treatments
PSODEEP1 Sweden
Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Sweden.
PSODEEP1 Denmark
Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Denmark.
PSODEEP1 Chile
Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in Chile.
PSODEEP1 Netherlands
Patients with self reported MD given diagnosis of psoriasis and/or psoriatic arthritis in the Netherlands.
Related Therapeutic Areas
Sponsors
Leads: Skane University Hospital
Collaborators: Karolinska Institutet, University of Copenhagen, University of Chile, Lund University

This content was sourced from clinicaltrials.gov